Transcript Highlights:

• Currently, Hawaii has two cannabinoid product regulatory systems, one for medical cannabis and one for
• Delta-9 THC is the intoxicating cannabinoid most prevalent in cannabis.
• So if you have a hemp gummy or a hemp drink with a cannabinoid in it, that is not FDA approved.
• When you extract the cannabinoids and put them into a product, it becomes the weight of the product and
• >> So there are currently two or three FDA-approved cannabinoid-based drugs.

Bills: HB1974, HB1853, HB1973, HB1574, HB2619, HB1966, HB1643, HB1671, HB2558, HB1854, HB2173, HB1575, HB2229, HB1535, HB1978, HB2508, HB1549, HB2187, HB1550, HB1977, HB2314, HB1871, HB2319, HB1591, HB1858, HB1898, HB2372, HB1765, HB2012, HB1706, HB1962, HB1963, HB1975, HB2009, HB2083, HB2224, HB1877, HB1959, HB1626, HB1665, HB2488, HB2456, HB2548, HB2207, HB1832, HB2079, HB1985, HB1618, HB2486, HB2242, HB2045, HB1703, HB2236, HB2480, HB1976, HB2287, HB2288, HB1777, HB276, HB1660, HB1676, HB1605, HB1751, HB1967, HB2383, HB2340, HB1946, HB2268, HB1950, HB2156, HB2118, HB1859, HB1863, HB1996, HB2114, HB2423, HB2429, HB2475, HB2534, HB2545, HB1813, HB1941, HB2474, HB2583, HB1576, HB1886, HB1939, HB2540, HB2590, HB2000, HB2163, HB2386, HB1691, HB1680, HB2516, HB1993, HB2442, HB1510, HB1958, HB1692

Keywords: HB1974, hearing loss, audiology, audiologist, hearing screening, hearing aids, cochlear implants, tele-audiology, communication access, assistive technology, speech-language pathology, deafness, hard of hearing, public health, kupuna, keiki, dementia, cognitive decline, fall prevention, State Health Planning and Development Agency

Transcript Highlights:

• And we disallow artificially derived cannabinoids from coming into the adult use side, which are allowed
• <01:25:47.200> uh disallow artificially derived uh disallow artificially derived uh cannabinoids
• um from coming into the cannabinoids um from coming into the adult<01:25:50.120> use<01:25:50.280
• Many times patients or adult use customers may be interested in products that have higher cannabinoids
• are more prevalent in hemp. cannabinoids other than THC, so CBD, cannabinoids other than THC, so CBD

Keywords: 1187, senate, all

Transcript Highlights:

• Synthetic cannabinoids killed Floridians every year and between 2020 excuse me 2022 2020 3 we saw a 50%
• increase in the number of deaths due to synthetic cannabinoids.
• We agree with removing synthetic cannabinoids from like Delta 8 from the market and we support common-sense

Keywords: 999, senate, all

Transcript Highlights:

• are an organic certified hemp license manufacturer in Newburyport, Massachusetts, and we focus on cannabinoid
• It's 100% dedicated to producing cannabinoids from hemp. We do not touch Delta-8.
• The cannabis plant produces all of these different cannabinoids, and we now have the science and the

Keywords: 995, all

Summary: The Joint Committee on Agriculture and Fisheries held its second hearing and heard testimony on a wide range of bills, including food security, cottage food entrepreneurship, hemp regulation, lobster industry support, pesticide restrictions, pollinator protections, pet cemeteries, and municipal land rights. Committee chairs outlined hearing procedures, noted that 19 bills were on the docket, and took testimony both in person and remotely, with several legislators testifying out of turn because of scheduling conflicts. Several speakers supported food access and local economic opportunity bills. Representative Howard and Senator Oliveira backed the Food Justice Frontline Program and a cottage food/food entrepreneur bill, arguing they would fund nonprofit food security organizations, create jobs, improve SNAP/HIP outreach, and reduce barriers for home-based food businesses. Eastie Farm representatives and a student testified in favor of the food justice bill, describing food insecurity in East Boston and the need for grants, youth involvement, and multilingual outreach. Sidney Travis of the Institute for Justice also supported cottage food reforms, saying current municipal permitting rules create unequal access and that cottage foods are generally safe. The committee also heard sharply divided testimony on hemp legislation. Senator Comerford supported S. 54 as a public health measure to ban synthetic THC products, restrict intoxicating hemp sales to licensed dispensaries, and fund local enforcement, while Laura Beiner, John Nathan, and Elizabeth Wendorf opposed the bill or parts of it, warning it would harm compliant hemp businesses and small farmers. Representative Arena-DeRosa testified in support of a related pollinator bill, and Adam Karachi opposed pesticide restrictions for schools while Deborah Smith supported them, arguing existing protections should be expanded to other child-centered locations. The committee also heard support for a bill to aid lobstermen affected by right whale protections, a bill to preserve private pet cemeteries, and a municipal right-of-first-refusal bill for agricultural and recreational land. No votes or final actions were taken during the hearing.

Transcript Highlights:

• We're talking about 0.5 milligrams of all other cannabinoids per serving.
• The burden of ease would be to limit some of these fees, allow functional cannabinoids to be used more
• One is the limits on non-intoxicating cannabinoids. CBD is one of those cannabinoids.
• Limiting the non-intoxicating cannabinoids to 25, which was now raised to 100 in HF 1615, I'm grateful
• And that's a simple fix if you just add the word intoxicating cannabinoids should be locked up because

Keywords: 1187, senate, all

Transcript Highlights:

• than they are with the impact of marijuana and similar products like hemp with intoxicants and cannabinoids
• than they are with the impact of marijuana and similar products like hemp with intoxicants and cannabinoids
• than they are with the impact of marijuana and similar products like hemp with intoxicants and cannabinoids

Keywords: March 14, 2026 - Regular Session Part 2, 976, house, all

Transcript Highlights:

• There are a few other cleanup provisions in there related to adjustments to the amount of cannabinoid
• c> I<00:08:25.680> also<00:08:25.919> own<00:08:26.000> a I also own a cannabinoid
• :54.080> on<00:18:54.240> non- The first issue is the limits on non-intoxicating cannabinoids

Keywords: 1183, house

Transcript Highlights:

• Synthetic cannabinoids kill Floridians every year.
• And between 2022 and 2023, we saw a 50% increase in the number of deaths due to synthetic cannabinoids
• We agree with removing synthetic cannabinoids, like Delta 8, from the market, and we support common-sense

Summary: The Committee on Fiscal Policy considered several bills and reported all of them favorably. SB 70-24, on state planning and budgeting, was presented as a modernization of the long-range planning program to simplify reporting, remove outdated measures, and focus on key data points and outcomes; it passed without opposition. CS/SB 166, on administrative efficiency in public schools, made broad changes to school accountability and operations, including lowering the stakes of certain student assessments, giving districts more flexibility on evaluations, contracts, certification, calendars, facilities, and VPK oversight. Two amendments were adopted: one clarifying that Title I funds may be used for STEM services, and another refining how advanced degrees count on salary schedules. The bill passed favorably after testimony both supporting and opposing the changes, with supporters emphasizing flexibility and opponents raising concerns about teacher evaluation and instructional practice. CS/SB 164, on vessel accountability, was described as a measure to address derelict and at-risk vessels by improving owner identification, creating a free long-term anchoring permit program, increasing penalties, and authorizing grants for local governments in the FWC prevention program. It received support from marine industry groups and was reported favorably. CS/SB 472, on education and correctional facilities for licensed professions, would allow inmates to receive credit toward licensure for qualifying coursework; a strike-all amendment added coordination with DBPR and professional boards. The bill drew support from criminal justice, business, and policy groups and passed unanimously. The committee spent the most time on CS/SB 438, on food and hemp products. Senator Burton and co-sponsor Senator Davis argued the bill was needed to regulate intoxicating hemp products, restrict child-appealing packaging and signage, ban synthetic hemp products, cap THC content in edibles and beverages, and require hemp beverages to be sold through alcohol-style distribution channels. Supporters, including alcohol distributors and some public safety advocates, said the bill would improve testing, labeling, and consumer protection. Opponents, including hemp retailers, farmers, and libertarian advocates, argued it would harm small businesses, reduce consumer choice, and push sales to the black market. After extensive debate, the bill was reported favorably. At the end of the meeting, senators requested to be recorded as voting in the affirmative on tab five, and the committee adjourned.

Transcript Highlights:

• HB 1246 will set up a uniform regulatory system to assure that all intoxicating cannabinoids will be
• Thank you so much for allowing the community to participate. cannabinoids hp1 1246 will set up a cannabinoids
• <00:46:26.040> also intoxicating cannabinoids also intoxicating cannabinoids also Laboratory
• Another point I'd like to make is actually our biggest concern right now are the hemp cannabinoids that
• are right now disguised, or sorry, the high-intoxicating THC that are now disguised as hemp cannabinoid

Keywords: 910, house, all

Summary: The House Committees on Judiciary and Hawaiian Affairs and Agriculture and Food Systems heard testimony and began decision-making on HB 1246, which would establish the Hawaii Cannabis and Hemp Office within DCCA to regulate cannabis. Chair Tarnas described the bill as divisive and noted the hearing had received 95 testimonies in support, 135 in opposition, and 11 comments. Members were told the office would be administratively attached to DCCA, and the department emphasized it would not direct day-to-day operations. DCCA also raised concerns about banking access due to federal law, while the Department of Agriculture supported a one-plant, one-agency approach and noted its current authority over cannabis plant importation and movement. Several agencies and advocates supported the bill with cautions or requested amendments. The Department of Health said it appreciated the bill’s public health protections but remained concerned about increased adult-use access, youth mental health, pregnancy-related risks, and effects on developing brains; it requested a 12-month delayed effective date. The Attorney General’s office said legalization should include safeguards, recommended a longer implementation timeline and seed funding, and flagged issues in the bill involving impaired driving, open-container language, and penalties for under-21 possession. The Office of the Public Defender supported the bill but objected to new driving and possession offenses, saying existing law already covers impaired driving. Doctors for Drug Policy Reform supported the measure, citing regulation of intoxicating cannabinoids, testing, childproof packaging, and public education as public-health benefits. Opponents focused on youth access, public safety, and the bill’s broader social effects. The Honolulu Police Department opposed the bill over access and diversion concerns, and the City and County of Honolulu Prosecutor strongly opposed legalization, citing higher-potency cannabis, youth harms, psychiatric risks, and increased poison-center calls. The Hawaiʻi Substance Abuse Coalition argued legalization should wait until prevention programs are in place and funded first, while the Hawaiʻi Family Forum and Hawaiian Republican Women also opposed the measure, citing concerns about youth exposure, added bureaucracy, and taxpayer costs. The Tax Foundation of Hawaiʻi questioned the purpose of the proposed cannabis taxes, asking why cannabis should be taxed heavily if legalization is intended. The hearing continued with additional testimony after a brief audio issue for one testifier.

Transcript Highlights:

• session when we did this bill reflects individuals in the state of Florida who have died due to cannabinoids
• and synthetic cannabinoids.
• There are deaths also of individuals who have cannabinoids in their system, but that's not the cause

Summary: The Committee on Agriculture heard a presentation from Florida FFA state officers Gabby Howell and Macy Jordan, who described FFA and agricultural education as a three-part model of classroom instruction, supervised agricultural experience, and leadership development. They highlighted FFA membership growth, Florida’s more than 60,000 members, industry certifications, and state funding that allows all agriculture education students to participate at no cost. Members praised the students and the organization’s role in developing future agricultural leaders. The committee then took up SB 438, which would regulate hemp and hemp extract products, including THC-infused beverages, by adding testing, labeling, retail location, age, and event restrictions, along with penalties and $2 million for testing equipment. Senator Burton said the bill is intended to address public safety, prevent products with illegal THC levels from reaching consumers, and respond to the governor’s prior veto concerns, especially store location and regulation. An amendment clarifying final batch testing was adopted without objection. Testimony was mixed. Supporters, including beverage distributors, law enforcement, and some hemp beverage businesses, backed regulation and said the bill would improve safety and clarity, though some asked for changes to avoid treating specialty beverage retailers like liquor stores. Opponents and some hemp industry representatives argued the bill was too restrictive, would hurt small businesses, and could push products into the black market; they also objected to THC limits, event restrictions, and the proposed regulatory structure. After debate, the committee voted 6-0 to report CS for SB 438 favorably.

Transcript Highlights:

• bringing on some new technologies and drugs that will help us with the new and emerging synthetic cannabinoids
• And drugs that will help us with the new and emerging synthetic cannabinoids and being able to better

Summary: The committee met with representatives from the Arkansas State Crime Lab for what members said was likely the first appearance by the lab before this committee. Lab officials gave an overview of the new crime lab facility now under construction, saying it is on schedule, under budget, and expected to be completed by the end of July next year, with phased move-in beginning around August 1. They explained that the current building is over 40 years old and overcrowded, with caseloads having doubled over the past 20 years, and said the new facility will improve workflow, add morgue capacity, and allow new technologies and equipment to be brought online. Members asked about staffing and recruitment, and the lab said recent pay changes and legislative support have made Arkansas more competitive for forensic specialists and medical examiners. Officials said vacancies have been reduced, a new deputy chief medical examiner has been hired, two more medical examiners are starting in August, and a new fellowship program has already attracted applicants. They also said the lab is prepared for the staffing needs of the new facility and that training periods remain long for many analyst positions. The discussion also covered rapid DNA, CODIS, sexual assault kit processing, genetic genealogy, and overdose-related data sharing. The lab said rapid DNA is in final testing with pilot agencies in Faulkner and Saline counties and could go live by the end of July, which would make Arkansas among the first states to do so. Officials described CODIS as a key investigative tool, said DNA profiles are entered automatically when they qualify, and reported that the sexual assault kit backlog has been cleared with the lab now maintaining a 60-day turnaround. They also confirmed Arkansas uses a kit-tracking system, works with private labs such as Othram and Bode for genetic genealogy, and is developing an overdose dashboard to share toxicology and overdose data with public health and law enforcement partners. Members praised the lab’s progress and the committee adjourned after announcing an August site visit to Lake Conway and the dam project.

Transcript Highlights:

• SB 3 by Perry relating to the regulation of consumable hemp products and the hemp-derived cannabinoids
• Of consumable hemp products and the hemp-derived cannabinoids contained in those products requiring a
• number SB. by Perry relating to the regulation of consumable hemp products and the hemp-derived cannabinoids
• It is important to note that hemp is defined as a cannabinoid plant with a percentage of Delta-9 THC.
• Finally, it will clarify that the milligram cap is specific to Delta-9 THC. and not all cannabinoids

Bills: SB31, SB33, SB20, SB217, SB264, SB269, SB650, SB681, SB528, SB502, SB740, SB916, SB995, SB10, SB2581, SB2570, SB3031, SB24, SB379, SB1171, SB1121, SB1120, SB1061, SB1036, SB1019, SB890, SB11, SB868, SB1188, SB1254, SB2778, SB2543, SB2443, SB1333, SB1259, SB1401, SB1404, SB2139, SB2165, SB2237, SB2268, SB1202, SB1198, SB1212, SB1451, SB1470, SB1498, SB965, SB1547, SB1667, SB1818, SB1902, SB2129, SB2078, SB2069, SB1737, SB1589, SB1318, SB387, SB1150, SB1574, SB2127, SB3034, SB860, SB1278, SCR5, SCR32, SB4, SB23, SB1762, SB34, SB60, SB706, SB1814, SB1220, SB523, SB565, SB1253, SB840, SB764, SB2383, SB2155, SB1535, SB1423, SB1566, SB1804, SB1728, SB1816, SB1952, SB75, SB2068, SB1455, SB213, SB627, SB2037, SB670, SB896, SB917, SB1184, SB971, SB1255, SB1261, SB1283, SB991, SB1733, SB21, SB231, SB739, SB1252, SB1371, SB646, SB3, SCR27, SB552, SB1405, SB1948, SB243, SJR1, SB31, SB33, SB20, SB217, SB264, SB269, SB650, SB681, SB528, SB502, SB740, SB916, SB995, SB10, SB2581, SB2570, SB3031, SB24, SB379, SB1171, SB1121, SB1120, SB1061, SB1036, SB1019, SB890, SB11, SB868, SB1188, SB1254, SB2778, SB2543, SB2443, SB1333, SB1259, SB1401, SB1404, SB2139, SB2165, SB2237, SB2268, SB1202, SB1198, SB1212, SB1451, SB1470, SB1498, SB965, SB1547, SB1667, SB1818, SB1902, SB2129, SB2078, SB2069, SB1737, SB1589, SB1318, SB387, SB1150, SB1574, SB2127, SB3034, SB860, SB1278, SCR5, SCR32, SB546, SB647, SB648, SB1493, SB1709, SB2001, HB5669, HB3115, HB5655, HB5675, HB5689, HB5690, HB5653, HB3228, HB2802, HB45, HB1318, HB5560, HB2894, HB4344, HB2775, HB33, HB 12, HB148

Keywords: SB 31, Life of the Mother Act, Texas abortion law, medical emergency, reasonable medical judgment, pregnancy complications, maternal health, life-threatening condition, ectopic pregnancy, spontaneous abortion, miscarriage, unborn child, abortion exception, abortion ban, physician liability, health care liability claim, aiding and abetting, Texas Medical Board, State Bar of Texas, continuing medical education

Bills: SB 10, SB 8, SB 15, SB 12, SB 6, SB 13, SB 9, SB 7, SB 17, SB 4

Keywords: sex designation, restroom access, civil penalties, private civil right of action, women's privacy, law enforcement, department file, employee records, misconduct, confidentiality, Texas occupations code, election laws, attorney general, prosecution, criminal offenses, criminal prosecution, jurisdiction, hemp, consumable hemp, hemp-derived cannabinoids

Transcript Highlights:

• is in section two of the bill, already prohibits the use of synthetic and artificially derived cannabinoids
• <00:30:42.320> in<00:30:42.519> manufactured<00:30:43.080> hemp cannabinoids in
• manufactured hemp cannabinoids in manufactured hemp products<00:30:44.279> however<00:30:44.480
• But the bill does not include or cover the terms that are used, cannabinoids, masking today on a lot
• Carla Lua continued: The bill does not include or cover the terms that are used, cannabinoids masking

Keywords: 910, house, all

Summary: The committee first heard House Bill 302, which would repeal the requirement that a provider-patient relationship for medical cannabis certification be established in person first. The Department of Health said it supported the House Draft 2 version as a way to expand patient access, and several testifiers from the medical cannabis community and dispensary industry supported the bill, especially for patients on outer islands or those unable to travel. One witness asked that earlier language removed in committee be restored to further improve access. Representative Shimizu asked whether follow-up in-person visits would still occur, and DOH responded that this varies by provider, with some continuing in-person care and others moving to telehealth for chronic conditions. The committee then took up House Bill 712, relating to the federal 340B drug pricing program and contract pharmacies. The Office of Consumer Protection and the Attorney General’s office both said they supported the bill’s purpose but wanted it clarified and possibly moved into a standalone chapter rather than chapter 481B. Supporters, including Hawaii Pacific Health and the Queen’s Health Systems, said the bill is needed to protect safety-net funding and access to discounted drugs, citing large financial benefits from 340B and losses caused by manufacturer restrictions on contract pharmacies. PhRMA opposed the bill, arguing the issue is not access to discounts but accountability and transparency in how contract pharmacies distribute benefits, and said it was willing to discuss amendments. Members asked follow-up questions about whether there was data showing misuse; PhRMA said it did not have numbers, while hospital witnesses said the program is federally audited and used appropriately in Hawaii. Finally, the committee heard House Bill 1482, HD1, which would tighten hemp and controlled-substance definitions to exclude Schedule I cannabinoids from manufactured hemp products and clarify the treatment of artificially derived cannabis. The Department of Health supported the measure, saying it adds clarity to existing prohibitions. Kūre Hawaii and other supporters said it would close loopholes involving Delta-8 and similar products. An individual testifier urged stronger language to also cover compounds such as HHC, THCA, THCP, and THCO. In response to questions about enforcement against mislabeled hemp products, DOH explained that THC percentages are relative to product weight, that some products can remain under the hemp threshold while still containing significant THC, and that hemp flower is already prohibited from direct retail sale, though enforcement can be complicated and involves both administrative and criminal authorities.

Transcript Highlights:

• epidemic of K2, Compounding this threat of physical violence is this epidemic of K2, a synthetic cannabinoid
• It would rightly classify synthetic cannabinoids like K2 as a controlled substance, giving law enforcement
• House Bill 2702 appropriately recognizes the dangers posed by synthetic cannabinoids such as K2, which

Keywords: 995, all

Summary: The committee heard testimony on a wide range of public safety bills, with strong support from law enforcement, advocates, and other stakeholders. Several measures focused on police and correctional officer wellness and protections, including bills on critical incident leave and post-incident support for officers, a bill to improve POST Commission representation, and a bill to protect correctional officers from assaults and exposure to synthetic drugs like K2. Witnesses described traumatic incidents, rising assaults in prisons, staffing shortages, and the need for confidentiality in peer-support debriefings. Committee members asked questions about assault classifications, K2 smuggling, tablet-related contraband, and whether counseling records would remain confidential. No votes were taken during the hearing. A major portion of the hearing was devoted to canine-related bills. Testimony supported creating a fund for retired police dogs and expanding emergency care training for working dogs injured in the line of duty. Speakers described police dogs as partners who locate suspects, missing persons, drugs, and weapons, and said retirement and medical costs are currently borne by handlers or nonprofits. The committee also heard testimony in favor of a purple alert system for missing people with intellectual and developmental disabilities, with advocates citing wandering risks, drowning dangers, and data from other states showing faster recovery times. The committee also heard testimony on a bill to expand the definition of sexual assault by an officer to cover situations beyond formal custody, including investigations and other encounters where police have coercive power. Advocates for sex workers and anti-trafficking organizations said the change would close a loophole, protect vulnerable people, and address documented abuses. In addition, testimony was taken on a bill to protect Massachusetts residents from federal surveillance through fusion centers, with critics calling for stronger oversight of BRIC and related databases. Representative Jeff Turco also testified on bills to change POST Commission membership, arguing for more law enforcement representation.

Transcript Highlights:

• point out to the committee significant issues with enforcement in the area of hemp and synthetic cannabinoids
• discussed what is necessary to increase the enforcement of the illegal hemp products and the illegal cannabinoids
• so we are just applying them now to the medical cannabis framework by uniformly regulating all cannabinoids
• so we are just applying them now to the medical cannabis framework by uniformly regulating all cannabinoids
• uniformly cannabis uh framework by uniformly regulating<00:46:20.160> all Regulating all cannabinoids

Keywords: 912, senate, all

Summary: The committee heard testimony on HB 302, which would expand access to medical cannabis by removing the in-person provider-patient relationship requirement and related restrictions. The Department of Health supported the bill, and multiple advocates and organizations testified in support, including the ACLU of Hawaii, Hawaii Alliance for Cannabis Reform, Marijuana Policy Project, and others. Supporters said the measure would improve access for patients, especially on outer islands, and some urged broader amendments allowing providers to certify cannabis for any medical condition and to speed registration and treat in-state and out-of-state patients equally. No opposition was heard, and the bill was left with no questions after testimony. The committee also heard HB 1052 HD1, which clarifies that the Public Utilities Commission may use universal service fund monies to provide free telecommunications access for individuals with print disabilities. Testimony was uniformly supportive from the DCCA Division of Consumer Advocacy, the State Council on Developmental Disabilities, the Department of Human Services, the Public Utilities Commission, and the National Federation of the Blind of Hawaii. Witnesses described the program as an important accessibility service that has been operating under prior appropriations and should continue under the universal service program. HB 1482, relating to controlled substances and hemp/synthetic cannabinoids, drew support from the Department of Law Enforcement, Department of Health, Honolulu Police Department, and others, with some comments from the Attorney General’s office. Supporters said the bill would clarify that delta-8 THC is a controlled substance and help enforcement against illegal hemp products and synthetic cannabinoids. Testimony and questioning focused on the need for better lab testing capacity, retail registry and age-gating, seizure authority, nuisance abatement, and possible use of special funds or appropriations to support enforcement. Members also discussed enforcement of illegal hemp businesses and whether additional funding or statutory changes would be needed. Finally, the committee took up HB 712, a 340B drug-discount measure affecting safety-net providers and contract pharmacies. Hospitals, health centers, and provider groups testified in support, saying the bill would protect access to discounted drugs and preserve funding for services such as chronic disease management, transportation, and specialty care. Pharmaceutical-industry representatives opposed the bill or sought amendments, arguing the 340B program has expanded beyond its original intent and lacks transparency, and they requested reporting or audit-like provisions to verify claims and revenues. Members questioned both sides about alleged abuse, the growth of contract pharmacies, and whether the bill should include transparency requirements before moving forward.

Transcript Highlights:

• We also have a Representative West provision that clarifies how combined cannabinoids are calculated,
• whether or not the named cannabinoids in law can be stacked or if it's in each.
• whether or not the named cannabinoids in law can be stacked or if it's in each.
• whether or not the named cannabinoids in law can be stacked or if it's in each.
• , whether or not the named cannabinoids in law can be stacked or if it's in each.

Keywords: 1183, house

Transcript Highlights:

• The third is the hemp-derived cannabinoid products.
• We picked up the hemp-derived cannabinoid program, which began at the Board of Pharmacy, then was at
• The third is the hemp-derived cannabinoid products.
• <00:18:23.000> products<00:18:24.000> uh the hemp deriv cannabinoid products uh the
• As I mentioned, we inherited the hemp-derived cannabinoid program from the Department of Health.

Keywords: 1183, house

Summary: The Minnesota House Commerce Committee held its inaugural meeting with Chair Tim O’Driscoll and co-chair Representative Greg Davids opening the session and inviting members to introduce themselves. Members briefly described their districts, business backgrounds, and priorities, with recurring themes including small business competitiveness, insurance and health care access, property and real estate issues, agriculture, and making Minnesota easier to do business in. Committee staff also introduced themselves and reminded members and testifiers about sign-in procedures and microphone use. The committee then heard an overview from Eric Toell, interim director of the Office of Cannabis Management, on the agency’s work and budget priorities. He said the office now oversees adult-use cannabis, medical cannabis, and hemp-derived cannabinoid products, has grown from about nine employees to 90 full-time staff plus temporary workers, and has been working with a Cannabis Advisory Council on testing, warning labels, and implementation issues. He also described outreach efforts, including webinars, newsletters, guidebooks for local governments, and office hours for applicants, along with enforcement of hemp-derived product rules through more than 3,000 inspections and an increase in compliance rates from about 35% to 75%. Toell also reported that the medical cannabis program has surpassed 51,000 patients and nearly 2,500 registered health care providers, and that a chronic pain report found more than a third of patients reported decreased pain. On the adult-use side, he said the office has posted proposed rules for public comment, plans to adopt them after review, and will open a licensing window from February 18 to March 14. He explained that the office is also managing community reinvestment grants and a technical assistance grant, with an emphasis on safeguards to ensure funds reach intended recipients. No votes were taken during this meeting.

Transcript Highlights:

• of certain products derived from hemp, including consumable hemp products and the hemp-derived cannabinoid

Keywords: 997, house, all

Transcript Highlights:

• In 2023 we were directed specifically to regulate the hemp-derived cannabinoids.
• So, we were told to immediately begin regulating hemp-derived cannabinoids.
• So the products, all the intoxicating products for hemp-derived cannabinoids now have to be regulated
• This is just like the hemp-derived cannabinoid stuff.
• We're doing all this work with the hemp-derived cannabinoids.

Keywords: 958, all

Summary: The committee first approved the minutes and then approved an agency amendment to a health and family services regulation. The amendment reversed a prior change so that neonatal ICU beds would remain subject to regular review rather than nonsubstantive review. The remaining administrative regulations were then reviewed without objection. The main presentation was from State Auditor Allison Ball on a report finding $836 million in concurrent Medicaid capitation payments from 2019 through 2022, involving individuals enrolled in Kentucky and at least one other state. Ball said Kentucky relied on the PARIS system, which has limitations because it is updated quarterly and depends on voluntary state participation, while a better federal data source, T-MSIS, was not fully available to the state. She said the audit found weak internal controls, siloed processes, outdated guidance, and a low-priority attitude toward residency checks, all of which contributed to missed alerts and improper payments. She also said the report identified additional problems, including payments made after beneficiaries died and cases involving multiple states paying for the same person. Ball recommended better access to federal data, stronger MCO contract provisions, and more active oversight by the Department for Medicaid Services and managed care organizations. She said the contracts reviewed did not provide a clear way to recoup the improper payments, though she and her counsel suggested possible equitable legal theories might be explored. Members expressed concern about the scale of the waste and the lack of contract enforcement, and asked whether any money could be recovered. Ball said the audit did not identify a clear contractual path to recoup the funds.